Latest news
MapLight Therapeutics stock crashes on Phase II schizophrenia data - Clinical Trials ArenaClinical Trials Arena · Tue, 28 Jul 2026 14:17:49 GMTMPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - TradingViewTradingView · Mon, 27 Jul 2026 23:08:32 GMTMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia - The Manila TimesThe Manila Times · Mon, 27 Jul 2026 11:17:27 GMTMapLight Therapeutics Says Phase 2 Schizophrenia Trial Meets Primary Endpoint - MoomooMoomoo · Mon, 27 Jul 2026 07:00:00 GMTPhase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia - Psychiatric TimesPsychiatric Times · Mon, 27 Jul 2026 07:00:00 GMTMaplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTMPLT: Phase 2 ZEPHYR met its primary endpoint, showing robust efficacy and cognitive benefit in schizophrenia - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMTMapLight Therapeutics (Nasdaq: MPLT) hits key Phase 2 goal in schizophrenia - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT